Literature DB >> 17038268

LDL-apheresis therapy.

Patrick M Moriarty1.   

Abstract

Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy. Despite its known benefit, apheresis is performed in only a minority of qualified patients. In addition to reducing plasma cholesterol, apheresis can alter other markers of vascular disease (inflammation, rheology, thrombosis, and fibrinolysis). The acute and chronic changes to the vascular system may warrant LDL-apheresis use in other diseases.

Entities:  

Year:  2006        PMID: 17038268     DOI: 10.1007/s11936-006-0049-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Mortality by cause for eight regions of the world: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

Review 2.  United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.

Authors:  S M Grundy
Journal:  Am J Cardiol       Date:  2001-10-11       Impact factor: 2.778

3.  LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects.

Authors:  Shuzo Kobayashi; Hidekazkeu Moriya; Kyouko Maesato; Kouji Okamoto; Takayasu Ohtake
Journal:  J Clin Apher       Date:  2005-12       Impact factor: 2.821

Review 4.  LDL apheresis.

Authors:  Gilbert R Thompson
Journal:  Atherosclerosis       Date:  2003-03       Impact factor: 5.162

5.  Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy.

Authors:  Tsukasa Nakamura; Yasuhiro Kawagoe; Hiroshi Ogawa; Yoshihiko Ueda; Masanori Hara; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

6.  Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.

Authors:  Tsukasa Nakamura; Takaharu Matsuda; Yukiko Suzuki; Yoshihiko Ueda; Hikaru Koide
Journal:  ASAIO J       Date:  2003 Jul-Aug       Impact factor: 2.872

7.  Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems.

Authors:  W Knisel; A Di Nicuolo; M Pfohl; H Müller; T Risler; M Eggstein; E Seifried
Journal:  J Intern Med       Date:  1993-11       Impact factor: 8.989

8.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

9.  Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.

Authors:  U Julius; W Metzler; J Pietzsch; T Fassbender; R Klingel
Journal:  Int J Artif Organs       Date:  2002-12       Impact factor: 1.595

10.  Plasma exchange in the management of homozygous familial hypercholesterolaemia.

Authors:  G R Thompson; R Lowenthal; N B Myant
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

View more
  3 in total

Review 1.  Problems and possible solutions for therapy with statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2013-06

2.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

3.  Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.

Authors:  Julia Lischka; Klaus Arbeiter; Charlotte de Gier; Andrea Willfort-Ehringer; Nina-Katharina Walleczek; Renata Gellai; Michael Boehm; Albert Wiegman; Susanne Greber-Platzer
Journal:  BMC Pediatr       Date:  2022-03-12       Impact factor: 2.567

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.